Dr. Thomas Ulas
Life & Medical Sciences Institute (LIMES)
t.ulas@uni-bonn.de View member: Dr. Thomas Ulas
RNA (New York, N.Y.)
The stem cell-specific RNA-binding protein TRIM71/LIN-41 was the first identified target of the pro-differentiation and tumor suppressor miRNA let-7. TRIM71 has essential functions in embryonic development and a proposed oncogenic role in several cancer types, such as hepatocellular carcinoma. Here, we show that TRIM71 regulates let-7 expression and activity via two independent mechanisms. On the one hand, TRIM71 enhances pre-let-7 degradation through its direct interaction with LIN28 and TUT4, thereby inhibiting let-7 maturation and indirectly promoting the stabilization of let-7 targets. On the other hand, TRIM71 represses the activity of mature let-7 via its RNA-dependent interaction with the RNA-Induced Silencing Complex (RISC) effector protein AGO2. We found that TRIM71 directly binds and stabilizes let-7 targets, suggesting that let-7 activity inhibition occurs on active RISCs. MiRNA enrichment analysis of several transcriptomic datasets from mouse embryonic stem cells and human hepatocellular carcinoma cells suggests that these let-7 regulatory mechanisms shape transcriptomic changes during developmental and oncogenic processes. Altogether, our work reveals a novel role for TRIM71 as a miRNA repressor and sheds light on a dual mechanism of let-7 regulation.
Published by Cold Spring Harbor Laboratory Press for the RNA Society.
PMID: 33975917
Life & Medical Sciences Institute (LIMES)
t.ulas@uni-bonn.de View member: Dr. Thomas UlasDeutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)
marc.beyer@dzne.de View member: PD Dr. Marc BeyerLife & Medical Sciences Institute (LIMES)
j.schultze@uni-bonn.de View member: Prof. Dr. med. Joachim L. SchultzeLife & Medical Sciences Institute (LIMES)
wkolanus@uni-bonn.de View member: Prof. Dr. Waldemar Kolanus